Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Biomolecular Structure and Dynamics

• Publication date

  2018-10-26

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/07391102.2017.1396255PMID 29064326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Investigation on the isoform selectivity of novel kinesin-like protein 1 (KIF11) inhibitor using chemical feature based pharmacophore, molecular docking, and quantum mechanical studies

  2016cited by this paper
• Interaction Entropy: A New Paradigm for Highly Efficient and Reliable Computation of Protein-Ligand Binding Free Energy.

  2016cited by this paper
• Design, biological evaluation and 3D QSAR studies of novel dioxin-containing triaryl pyrazoline derivatives as potential B-Raf inhibitors.

  2016cited by this paper
• Molecular dynamics in drug design.

  2015cited by this paper
• Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells

  2015cited by this paper
• Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.

  2015cited by this paper
• Anti-HIV Drug Development Through Computational Methods

  2014cited by this paper
• Structure‐Based Design of New KSP‐Eg5 Inhibitors Assisted by a Targeted Multicomponent Reaction

  2014cited by this paper
• Synthetic studies on mitotic kinesin Eg5 inhibitors: synthesis and structure-activity relationships of novel 2,4,5-substituted-1,3,4-thiadiazoline derivatives.

  2014cited by this paper
• A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors

  2014cited by this paper
• Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes.

  2014cited by this paper
• Kinesin Spindle Protein (KSP) Inhibitors in Combination with Chemotherapeutic Agents for Cancer Therapy

  2013cited by this paper
• Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism.

  2013influential reference
• “Snapshots” of Ispinesib-induced Conformational Changes in the Mitotic Kinesin Eg5*

  2013influential reference
• Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.

  2013cited by this paper
• PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data.

  2013cited by this paper
• Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity†

  2012cited by this paper
• The discovery of tetrahydro-beta-carbolines as inhibitors of the kinesin Eg5.

  2012influential reference
• Synthesis and Biological Evaluation of Thiophene Derivatives as Acetylcholinesterase Inhibitors

  2012cited by this paper
• Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.

  2012influential reference
• CPUYJ039, a newly synthesized benzimidazole‐based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity

  2011cited by this paper
• Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.

  2011cited by this paper
• Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.

  2011cited by this paper
• Abstract A86: A phase 1 study of LY2523355, an Eg5 inhibitor, administered on Days 1, 2, and 3 with or without pegfilgrastim in patients with advanced malignancy (NCT01214629).

  2011cited by this paper
• A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

  2011cited by this paper
• Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking

  2011cited by this paper
• The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5.

  2010cited by this paper
• SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

  2010cited by this paper
• Mitotic force generators and chromosome segregation

  2010cited by this paper
• Successful applications of computer aided drug discovery: moving drugs from concept to the clinic.

  2010cited by this paper
• How kinesin motor proteins drive mitotic spindle function: Lessons from molecular assays.

  2010cited by this paper
• Abstract 2750: ARQ 621, a novel potent and selective inhibitor of Eg5: Preclinical data and early results from a clinical phase 1 study

  2010cited by this paper
• Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.

  2010cited by this paper
• An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex.

  2009cited by this paper
• A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL).

  2009cited by this paper
• ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.

  2009cited by this paper
• A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)

  2009cited by this paper
• Structure-based drug design and modern medicine.

  2009cited by this paper
• An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors.

  2009cited by this paper
• Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications

  2008cited by this paper
• Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP.

  2008cited by this paper
• Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.

  2008cited by this paper
• Docking studies on kinesin spindle protein inhibitors: an important cooperative ‘minor binding pocket’ which increases the binding affinity significantly

  2007cited by this paper
• Kinesin-5 acts as a brake in anaphase spindle elongation.

  2007cited by this paper
• Pharmacophore identification of KSP inhibitors.

  2007cited by this paper
• Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP.

  2007influential reference
• Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.

  2007cited by this paper
• Kinesin Spindle Protein (KSP) Inhibitors. Part 2. The Design, Synthesis, and Characterization of 2,4‐Diaryl‐2,5‐dihydropyrrole Inhibitors of the Mitotic Kinesin KSP.

  2006cited by this paper
• Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.

  2006cited by this paper
• Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method.

  2006cited by this paper
• Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.

  2006cited by this paper
• Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring.

  2006cited by this paper
• Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors.

  2006cited by this paper
• Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP.

  2006cited by this paper
• Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line

  2006cited by this paper
• Antitumor activity of a kinesin inhibitor.

  2004cited by this paper
• UCSF Chimera—A visualization system for exploratory research and analysis

  2004cited by this paper
• Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm

  2003cited by this paper
• HR22C16: a potent small-molecule probe for the dynamics of cell division.

  2003cited by this paper
• Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.

  2003cited by this paper
• Molecular properties that influence the oral bioavailability of drug candidates.

  2002influential reference
• Crystal Structure of the Mitotic Spindle Kinesin Eg5 Reveals a Novel Conformation of the Neck-linker*

  2001cited by this paper
• A smooth‐particle mesh Ewald method for DL_POLY molecular dynamics simulation package on the Fujitsu VPP700

  2000cited by this paper
• Solid phase synthesis of tertiary amines on amide REM resins: Grignard and metal hydride compatible resins.

  2000cited by this paper
• Spindle assembly in animal cells.

  2000cited by this paper
• Kinesin and dynein superfamily proteins and the mechanism of organelle transport.

  1998cited by this paper
• Phosphorylation by p34cdc2 Protein Kinase Regulates Binding of the Kinesin-related Motor HsEg5 to the Dynactin Subunit p150Glued *

  1997cited by this paper
• Molecular phylogeny of the kinesin family of microtubule motor proteins.

  1994cited by this paper
• Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.

  1992cited by this paper
• Molecular dynamics with coupling to an external bath

  1984influential reference
• Comparison of simple potential functions for simulating liquid water

  1983cited by this paper
• Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes

  1977cited by this paper

• Synthesis, Anticancer Screening, and In Silico Evaluations of Thieno[2,3-c]pyridine Derivatives as Hsp90 Inhibitors

  2025cites this paper
• Therapeutic potential of Abutilon indicum (L.) Sweet seed extract in PCOS: Insights from mass spectrometry, network pharmacology, and molecular docking

  2025cites this paper
• A virtual insight into mushroom secondary metabolites: 3D-QSAR, docking, pharmacophore-based analysis and molecular modeling to analyze their anti-breast cancer potential

  2024cites this paper
• A novel antibody-KSP inhibitor conjugate improves KSP inhibitor efficacy in vitro and in vivo.

  2023cites this paper
• Identification of Potential Lead Compounds Targeting Novel Druggable Cavity of SARS-CoV-2 Spike Trimer by Molecular Dynamics Simulations

  2023cites this paper
• Identification of BACE-1 Inhibitors against Alzheimer’s Disease through E-Pharmacophore-Based Virtual Screening and Molecular Dynamics Simulation Studies: An Insilco Approach

  2023cites this paper
• Design, Synthesis, Anticancer Screening and Molecular Modelling Studies of Novel Thiazoles

  2023cites this paper
• Advances in research on potential inhibitors of multiple myeloma.

  2023cites this paper
• Structural based investigation of novel pyrazole-thiazole Hybrids as dual CDK-1 and CDK-2 inhibitors for cancer chemotherapy

  2022cites this paper
• 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach

  2022cites this paper
• Thiazolopyrimidine Scaffold as a Promising Nucleus for Developing Anticancer Drugs: a Review in Last Decade.

  2022cites this paper
• Drug Discovery of Plausible Lead Natural Compounds That Target the Insulin Signaling Pathway: Bioinformatics Approaches

  2022cites this paper
• Standardization, in-silico and in-vivo safety assessment of methanol extract of Ziziphus mauritiana Lam leaves.

  2022cites this paper
• Use of Molecular Docking as a Decision-Making Tool in Drug Discovery

  2021cites this paper
• Novel thiomorpholine tethered isatin hydrazones as potential inhibitors of resistant Mycobacterium tuberculosis.

  2021cites this paper
• Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach

  2021cites this paper
• mRNAs biomarker related to the control of proliferation and cell death in HepG2/C3A spheroid and monolayer cultures treated with piperlongumine

  2020cites this paper
• Synthesis, Biological Assessment, and Structure Activity Relationship Studies of New Flavanones Embodying Chromene Moieties

  2020cites this paper
• Eg5 Targeting Agents : From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.

  2020cites this paper
• Drug-Receptor Interactions

  2020cites this paper
• In silico approach of naringin as potent phosphatase and tensin homolog (PTEN) protein agonist against prostate cancer

  2020cites this paper
• Cadmium-induced conformational changes in type 2 metallothionein of medicinal plant Coptis japonica: insights from molecular dynamics studies of apo, partially and fully metalated forms

  2019cites this paper
• Pharmacophore Development

  2019cites this paper
• Biochemical characterisation of human KifC1 and Eg5, two potential targets for drug development in cancer chemotherapy

  2019cites this paper
• Discovery of novel N-methyl carbazole tethered rhodanine derivatives as direct inhibitors of Mycobacterium tuberculosis InhA.

  2019cites this paper
• Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: Cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation

  2019cites this paper
• Computational Drug Designing and Prediction Of Important Parameters Using in silico Methods- A Review.

  2019cites this paper
• Protein-Ligand Interaction Energy-Based Entropy Calculations: Fundamental Challenges For Flexible Systems.

  2018cites this paper
• Design and synthesis of novel thiadiazole-thiazolone hybrids as potential inhibitors of the human mitotic kinesin Eg 5

  2018cites this paper
• Design and synthesis of novel thiadiazole-thiazolone hybrids as potential inhibitors of the human mitotic kinesin Eg5.

  2018cites this paper
• Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs

  2018cites this paper